Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Other Operating Expenses (2023 - 2025)

Immunome's Other Operating Expenses history spans 3 years, with the latest figure at $10.0 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 63.47% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, down 93.44%, while the annual FY2025 figure was $10.0 million, 93.44% down from the prior year.
  • Other Operating Expenses reached $10.0 million in Q4 2025 per IMNM's latest filing, down from $27.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $112.0 million in Q1 2024 to a low of $6.3 million in Q2 2024.
  • Average Other Operating Expenses over 3 years is $40.5 million, with a median of $18.7 million recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: tumbled 66.12% in 2024, then plummeted 63.47% in 2025.
  • A 3-year view of Other Operating Expenses shows it stood at $80.8 million in 2023, then crashed by 66.12% to $27.4 million in 2024, then tumbled by 63.47% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Other Operating Expenses are $10.0 million (Q4 2025), $27.4 million (Q4 2024), and $6.7 million (Q3 2024).